✦ LIBER ✦

The Impact of Fewer Hip Fractures with Risedronate Versus Alendronate in the First Year of Treatment: Modeled German Cost-Effectiveness Analysis

✍ Scribed by Melissa Thompson; Margaret Pasquale; Daniel Grima; Werner Moehrke; Hans Peter Kruse

Book ID: 109079117
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 190 KB
Volume: 13
Category: Article
ISSN: 1098-3015
DOI: 10.1111/j.1524-4733.2009.00666.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effectiveness of bisphosphonates on nonv

Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study

✍ S. L. Silverman; N. B. Watts; P. D. Delmas; J. L. Lange; R. Lindsay 📂 Article 📅 2006 🏛 Springer-Verlag 🌐 English ⚖ 301 KB

Effects of 1 to 3 years' treatment with

Effects of 1 to 3 years' treatment with alendronate on mechanical properties of the femoral shaft in a canine model: Implications for subtrochanteric femoral fracture risk

✍ David B. Burr; Tamim Diab; Andrew Koivunemi; Mark Koivunemi; Matthew R. Allen 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 78 KB 👁 2 views

## Abstract Bisphosphonate (BP) treatment used to prevent bone loss in postmenopausal osteoporosis has recently been implicated in an apparent increase in subtrochanteric femoral fractures. Previous work showed that BPs can reduce the energy to fracture of cancellous bone, but limited data exist on

Cost-effectiveness analysis of anastrozo

Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial

✍ Gershon Y. Locker; Robert Mansel; David Cella; Deborah Dobrez; Sonja Sorensen; S 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 267 KB